Maufacturers report consistent, long-term improvement in patients with axial spondyloarthritis treated with ixekizumab over two years in phase 3 study

In the COAST-Y study, 56.7% of patients treated ixekizumab 80 mg every four weeks achieved ASAS40 at 2 years, with 43.9% of patients achieving low disease activity status and 19.7% achieving partial remission.

Source:

Biospace Inc.